Khan Capital | April 2026
Key Takeaways
- A 100% headline tariff on imported patented pharmaceuticals: the executive order signed on 2 April 2026, exactly one year after Liberation Day, is the most aggressive trade action ever taken against the global pharmaceutical supply chain.
- The structure is graduated, not flat: compliance pathways and bilateral allied carve-outs (EU, Japan, Korea, Switzerland and the UK) split the sector into a small group of exempt winners and a much larger group of exposed losers, as detailed in the table below.
- $150 billion in onshoring commitments has already been extracted from compliant blue-chip pharma names, anchoring a multi-year US capital expenditure cycle that will outlast any single political administration.
- Section 232 metals tariffs were simultaneously restructured to apply to full customs value rather than metal content alone, raising input costs across construction, automotive, electrical grid, and consumer electronics supply chains.
- The effective US tariff rate now sits at 13.7%, the highest sustained level since the early 1940s, and the Supreme Court’s IEEPA ruling has already invalidated the legal foundation of the original Liberation Day framework.
Part of: Tariffs & the Trade War – Khan Capital’s hub on tariffs and the trade war.
On 2 April 2026, exactly one year after the original Liberation Day proclamation, President Trump signed an executive order imposing tariffs of up to 100% on imported patented pharmaceutical products. The announcement, paired with a simultaneous restructuring of Section 232 metals tariffs, represents the administration’s most significant trade policy escalation since the Supreme Court struck down the IEEPA tariff framework in February. For pharmaceutical equities, healthcare costs, fixed income markets, and the broader reshoring narrative, the Trump pharmaceutical tariffs mark a turning point that will take quarters, not weeks, to fully price.
Inside the Trump Pharmaceutical Tariffs
The order targets patented (branded) pharmaceutical products and their active ingredients. Generic drugs and biosimilars are exempt for now, though the White House has indicated this carve-out will be reassessed within twelve months. Rather than a blanket 100% rate, the order layers two distinct pricing mechanisms: a compliance-based ladder for individual companies (most-favoured-nation pricing plus US manufacturing buys exemption) and a bilateral ladder for trading partners (negotiated rates for allied exporters). The full architecture is summarised in the table below.
The deliberate intent of this two-axis structure is to convert the tariff from a simple trade barrier into a negotiating lever, giving the administration the ability to offer targeted relief in exchange for commitments on drug pricing and domestic investment. Large pharmaceutical importers have 120 days to comply before the headline rate takes effect; smaller producers have 180 days.
| Category | Tariff Rate | Conditions |
|---|---|---|
| Full compliance | 0% | MFN pricing deal + active US manufacturing |
| Onshoring without pricing deal | 20% (rising to 100%) | US facility under construction, no MFN agreement |
| No compliance | 100% | No onshoring, no pricing deal |
| EU, Japan, South Korea, Switzerland | 15% | Bilateral trade agreement in place |
| United Kingdom | 10% | Bilateral trade agreement in place |
| Generics, biosimilars | 0% (under review) | Exempt for 12 months; reassessment pending |
The Allied Carve-Outs
The bilateral carve-outs matter more than the headline rate for the simple reason that the EU, Switzerland, and Japan collectively account for the majority of branded pharmaceutical exports to the United States. The practical effect is that the 100% rate falls hardest on imports from countries without a bilateral deal: principally China, Singapore, and to a lesser extent India, whose exports to the US are weighted toward generics rather than branded drugs. The two-tier system reinforces the broader administration playbook of using trade access as a reward for diplomatic alignment, a pattern visible across the Section 232 metals architecture and the surviving fragments of the original Liberation Day order.
Winners and Losers: The Pharma Sector Bifurcation
The market reaction has been defined by a sharp split between companies that moved early and those that did not. Pfizer led the compliance wave, committing $70 billion to domestic manufacturing and agreeing to most-favoured-nation pricing across its entire US portfolio in exchange for a 0% rate. The stock has rallied 37% from its 52-week low. Eli Lilly followed a similar path, pledging over $50 billion to US manufacturing projects and agreeing to distribute its weight-loss blockbuster Zepbound through the federal TrumpRx.gov discount portal. Johnson & Johnson, Merck, and Bristol Myers Squibb have each filed letters of intent for their own onshoring deals.
The other side of the split is less comfortable. Smaller biotechs and mid-cap pharmaceutical companies that import active ingredients or finished products from non-allied nations face a binary choice: absorb the tariff (compressing already thin margins), pass it through to buyers (risking volume loss), or begin the multi-year process of onshoring production. For companies with limited balance sheets, the compliance window is tight and the capital required to build US manufacturing capacity is substantial. The result is a structural divergence between large-cap exempt names and the long tail of mid- and small-cap exposed names that is likely to persist for several quarters.
Section 232: Steel, Aluminium, and Copper Restructured
The pharmaceutical order was not the only Liberation Day anniversary action. The administration simultaneously issued a proclamation restructuring Section 232 tariffs on steel, aluminium, and copper, effective 6 April. Articles made entirely or substantially of these metals now face a flat 50% tariff on their full customs value. Derivative products substantially made of the same metals face 25%. Products containing 15% or less metal content are exempt.
The most consequential change is the shift to full customs value as the tariff base. Previously, Section 232 duties applied only to the metal content of an imported article. Assessing the duty against the entire value of the product significantly increases the effective tariff on manufactured goods, with downstream effects for construction, automotive, electrical grid equipment, and consumer electronics. Certain industrial and grid equipment categories receive a temporary 15% rate through 2027 to avoid disrupting the domestic infrastructure buildout.
Liberation Day: One Year On
The anniversary provides a natural point to assess the broader regime’s track record. The picture is contested. The Tax Foundation’s analysis shows manufacturing employment has fallen by 89,000 jobs since April 2025, the trade deficit has not narrowed in the way the administration initially projected, and the Supreme Court’s February 2026 ruling invalidated the IEEPA legal basis underpinning the original Liberation Day order. Inflation, at 2.4% in February, remains above target, with Federal Reserve Chair Jerome Powell attributing much of the goods-sector price pressure to tariff effects.
The effective US tariff rate, which peaked near 27% in mid-2025, now stands at approximately 13.7% after the Supreme Court ruling and various bilateral adjustments. That is still roughly five times the pre-Liberation Day rate and represents the highest sustained tariff level since the early 1940s. The Yale Budget Lab estimates the cumulative consumer impact at roughly $1,500 per US household in 2026, a figure that does not yet incorporate the pharmaceutical or revised metals tariffs.
The administration disputes these assessments, pointing to over $400 billion in announced domestic manufacturing commitments across pharmaceutical and industrial sectors as evidence the strategy is succeeding in its core objective of reshoring production. The pharmaceutical pledges anchor a meaningful share of that figure, though the gap between announced and completed investment remains wide.
Financial Markets Impact
Equities: sector and style. The Health Care Select Sector SPDR (XLV) initially sold off on the announcement before recovering as the compliance pathway became clearer, ending the week roughly flat. Beneath that surface calm, the dispersion has been violent: large-cap exempt names have outperformed the broader sector by double digits since 2 April, while the iShares Biotechnology ETF (IBB), which carries heavier exposure to mid- and small-cap names without onshoring commitments, has lagged the S&P 500 by approximately seven percentage points over the same window. The split favours quality and balance-sheet strength within healthcare and is likely to persist until the compliance deadlines pass and the picture of who has secured exemptions and who has not is fully crystallised.
| Asset / Sector | Direction | Driver |
|---|---|---|
| Large-cap exempt pharma (PFE, LLY, MRK, BMY) | Positive | 0% rate plus regulatory moat from compliance |
| Mid-cap biotech and generics distributors | Negative | Margin compression and onshoring capex burden |
| Construction and specialty engineering | Positive | Pharma facility buildout (multi-year capex) |
| Healthcare REITs (life sciences focus) | Positive | Increased demand for US lab and production space |
| 5y breakeven inflation | Higher | Pass-through of pharma and metals tariffs |
| Long-end Treasuries (10y, 30y) | Yields up | Reduced 2026 cut probability, term premium |
| US dollar (DXY) | Mixed/firmer | Tariff revenue plus delayed Fed cuts |
| Indian generic exporters (ADRs) | Negative overhang | 12-month generics review window |
Fixed income: inflation and the Fed path. The bond market has read the announcement primarily through an inflation lens. Five-year breakeven inflation rates ticked up roughly 8 basis points in the two sessions following the executive order, with the move concentrated in the goods component of inflation expectations. Fed funds futures now imply a meaningfully lower probability of a 2026 rate cut than they did before the announcement: the path that briefly looked viable after the IEEPA ruling has narrowed again. Long-end Treasuries have sold off modestly as term premium has rebuilt, and the 2s10s curve has steepened by roughly 6 basis points. For duration-sensitive portfolios, the takeaway is that tariff-driven goods inflation acts as a structural headwind to the very rate cuts that would otherwise support fixed income returns.
Currencies and commodities. The dollar has firmed modestly against the euro and yen on the combination of tariff revenue inflows, narrower expected rate differentials, and the relative insulation of the US economy from second-round trade retaliation. Gold has benefited from the broader uncertainty about the durability of the trade regime and remains bid as a hedge against both inflation surprise and a contested policy environment. Copper, which sits squarely inside the Section 232 restructuring, has held a firm bid on the combination of tariff-induced supply tightness and the construction demand that the pharmaceutical onshoring buildout itself will generate.
Healthcare REITs and the supply chain. One of the less obvious beneficiaries is the segment of healthcare and life-sciences real estate that owns purpose-built lab and production space. The pledged $150 billion in onshoring capital must land somewhere physical, and the existing US footprint of pharmaceutical manufacturing capacity is too small to absorb it without significant new construction. Companies in specialty chemicals, pharmaceutical-grade equipment, cleanroom systems, and industrial automation that supply this buildout sit in a multi-year demand window that is largely insulated from short-term equity volatility. Investors looking for tariff-related exposure with lower direct policy risk may wish to consider the picks-and-shovels supply chain rather than the pharmaceutical end-buyers themselves.
Generics overhang. The temporary nature of the generics exemption creates a visible tail risk for Indian generic exporters, US generic distributors, and the pharmacy benefit managers whose cost models depend on cheap generic supply. A 2027 decision to extend the tariff to generics would compress margins across this entire chain and would also feed into healthcare-cost inflation in a way that the branded-only tariff does not. Positioning that depends on a continuation of the generics carve-out should be sized with that overhang in mind.
What to Watch Next
The next critical dates are the compliance deadlines: early August 2026 for large pharmaceutical companies and late September for smaller producers. Between now and then, the market will closely track which firms sign MFN deals, which announce onshoring commitments, and which choose to absorb or pass through the tariff. The Federal Reserve’s response is also relevant: if pharmaceutical price increases feed through to core CPI, the already narrow path to a rate cut in 2026 becomes narrower still. Beyond the immediate calendar, the broader question is whether the tariff-as-negotiating-lever model represents a durable shift in US trade policy or a framework that will be unwound by legal challenge, retaliation, or political change. The scale of the commitments it has already extracted from the pharmaceutical sector suggests the model is, at minimum, producing the onshoring outcomes the administration set out to achieve.
Conclusion
The April 2026 pharmaceutical tariffs are best understood not as a single trade action but as the maturing of a broader policy template. By converting tariff exposure into a function of corporate behaviour and bilateral diplomatic alignment, the administration has produced the largest sector-specific reshoring commitment of the modern era while simultaneously creating a sharply bifurcated market within healthcare. For investors, the implications cut across equities, fixed income, currencies, and real assets. The story is no longer simply about pharma. It is about how a credible threat of high tariffs, paired with selective relief, can rewire capital allocation across an entire sector, and whether that template will hold against the legal and political headwinds it now faces.
Sources: White House: Pharmaceutical Tariff Fact Sheet · CNBC: Trump Pharmaceutical Tariffs of Up to 100% · BioPharma Dive: Trump Revives Pharma Tariffs · White House: Section 232 Metals Tariff Fact Sheet · Tax Foundation: Liberation Day One Year On · Yale Budget Lab: State of US Tariffs · Investing.com: 5 Pharma Stocks Exempt From Tariffs
The Khan Capital Brief
Understand what moves markets
Analysis like this, free in your inbox. No spam, unsubscribe any time.
Related Reading: The legal foundation of the original Liberation Day tariffs was dismantled by the judiciary in Supreme Court Strikes Down Trump’s IEEPA Tariffs in Landmark 6-3 Ruling. The Federal Reserve’s response to the inflationary pressures created by both tariffs and the Iran conflict is examined in Fed Holds Amid Iran War: Walking the Tightrope Between Jobs and Inflation. The broader first-quarter market damage, to which trade policy uncertainty contributed, is chronicled in Q1 2026: The Worst First Quarter Since 2022. The defence and energy sectors that may partially offset metals tariff costs through government contracts are profiled in Defence, Energy, and Gold: The 2026 Geopolitical Portfolio. For the fundamentals, start with IEEPA tariffs, explained. See also the term premium, explained.
Leave a Reply